文献速递妇科产科

BRCA突变女性卵巢癌早期检测:CA125与HE4双标志物纵向算法开发

Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
PubMed 文献 · Gynecol Oncol · 2020-10-01

本研究在BRCA突变且卵巢完整的女性中开发了结合CA125与HE4的纵向风险算法(ROCA),每四个月检测一次,异常风险触发超声。双标志物ROCA的异常率(8%)显著低于标准护理监测(15%,p=0.042),转诊超声的假阳性率为6.6%(特异性93.4%),转诊手术咨询的假阳性率为1.7%(特异性98.3%)。结论认为双标志物ROCA值得在更大试验中进一步评估敏感性。

要点

  • 双标志物ROCA每4个月检测CA125和HE4,异常风险触发超声。
  • 双标志物ROCA异常率8%,显著低于标准护理监测的15%。
  • 双标志物ROCA转诊超声假阳性率6.6%,转诊手术咨询假阳性率1.7%。

核心结论

  • 新开发的双标志物ROCA每4个月 administered 一次,其回调率低于标准护理监测。
  • 双标志物ROCA已建立高特异性,值得在更大试验中进一步评估敏感性。

研究设计与样本

  • 前瞻性研究纳入BRCA突变且卵巢完整的女性,ROCA组149人,标准护理组43人。
  • 每4个月检测血清CA125和HE4,采用ROCA识别较基线显著升高,异常风险触发后续超声。
  • 先后使用仅CA125的ROCA、HE4的ROCA,最终实施结合两标志物的ROCA,并与标准护理监测策略比较。

主要发现

  • ROCA CA125检测异常率为24%,单独使用ROCA CA125或新型ROCA HE4时为16%,双标志物ROCA降至8%。
  • 双标志物ROCA异常率8%显著低于标准护理组的15%(p=0.042)。
  • 无卵巢癌女性中,双标志物ROCA转诊超声的平均假阳性率为6.6%(特异性93.4%)。
  • 双标志物ROCA加超声转诊手术咨询的平均假阳性率为1.7%(特异性98.3%)。

临床怎么用

  • 对于BRCA突变且卵巢完整的女性,可考虑每4个月使用双标志物ROCA进行监测,以降低回调率。
  • 双标志物ROCA异常风险触发超声,高特异性有助于减少不必要的转诊。

局限性

  • 双标志物ROCA的敏感性尚未在更大试验中评估。
  • ROCA组149人,标准护理组43人,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop a longitudinal algorithm combining two biomarkers, CA125 and HE4, for early detection of ovarian cancer in women with BRCA mutations. METHODS: Women with BRCA mutations and intact ovaries were invited to participate in a novel ovarian cancer early detection prospective study. The Risk of Ovarian Cancer Algorithm (ROCA) identifying significant increases above each woman's baseline in serum CA125 and HE4 was performed every four months; abnormal risks triggered a subsequent ultrasound. The study first used a risk algorithm for only CA125, a second algorithm was developed for HE4 and finally a risk algorithm combining the two biomarkers was implemented. The ROCA strategy was compared to Standard of Care (SOC) surveillance strategy. RESULTS: A total of 149 women enrolled in the ROCA arm while 43 women enrolled in the SOC arm. Abnormal scores were found in 24% of ROCA CA125 tests, 16% if ROCA CA125 or the novel ROCA HE4 were used independently and reduced to 8% using the new two-marker ROCA, significantly lower than the 15% of abnormal tests seen in the SOC arm (p = 0.042). The average false positive rate among women without ovarian cancer for two-marker ROCA for referral to ultrasound was 6.6% (specificity 93.4%), and for the two-marker ROCA plus ultrasound for referral to surgical consultation was 1.7% (specificity 98.3%). CONCLUSION: A newly developed two-marker ROCA administered every 4 months had lower call-back rates than SOC surveillance. Having established high specificity, the two-marker ROCA score deserves further evaluation for sensitivity in a larger trial.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lentz SE, Powell CB, Haque R, et al. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations. Gynecol Oncol. 2020. PMID: 33012551. doi:10.1016/j.ygyno.2020.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。